Orphan drugs

Demyelination of neuron
#Antisense Oligonucleotides (ASOs) #FDA #Orphan drugs #Rare disease #SynaptixBio

FDA Orphan Drug Designation awarded to rare disease therapies

UK-based biotech SynaptixBio has secured a second Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA). The company received its first ODD in early 2023 for a therapeutic that targets Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC), the most severe form of TUBB4A leukodystrophy. Read More

#News #Regulatory

Rare Disease Day
#Orphan drugs #Rare cancers #Rare disease #Rare Disease Day

Five 2024 breakthroughs in the treatment of rare diseases

For Rare Disease Day 2024, Diana Spencer provides a round-up of the latest breakthroughs in the treatment of rare disease. Study reveals therapeutic potential of mRNA in rare diseases Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare… Read More

#News

#AnaMar #Autoimmune disease #European Medicines Agency #FDA #Fibrotic disease #Orphan drugs

Dual-action treatment for fibrotic disease secures orphan drug status

AM1476, a first-in-class, peripheral-acting serotonin receptor antagonist, has been granted US and EU Orphan Drug Designation as an anti-fibrotic treatment for systemic sclerosis. AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist that can be delivered orally. It has demonstrated efficacy in in vitro and in vivo models of… Read More

#News #Regulatory

FDA headquarters
#Acute inflammatory conditions #FDA #Orphan drugs #Phase II trial #Revolo Biotherapeutics

Immune-resetting peptide gets orphan drug status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revolo Biotherapeutics’ ‘1104 to treat eosinophilic esophagitis (EoE). EoE is a chronic, allergic inflammatory disease that is characterised by the accumulation of eosinophils in the lining of the esophagus. Inflammation caused by immune cells such as T… Read More

#News #Regulatory

Blood cancer
#Acute Myeloid Leukaemia #FDA #Oncology #Orphan drugs #Pleco Therapeutics #Rare disease

Novel leukaemia drug receives FDA Orphan Drug Designation

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. The FDA’s designation acknowledges the potential of PTX-252… Read More

#Cancer Research #News #Regulatory

Pancreatic cancer
#AI #ASCO #Cancer research #Clinical trials #FDA #Neurology #Oncology #Orphan drugs #Pancreatic cancer #Rare disease

Phase IIa results for combination pancreatic cancer therapy  

BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, has announced new data from a Phase IIa clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held 18-20 January 2024, in San Francisco. Read More

#Cancer Research #News

Lung cancer
#FDA #Non-small cell lung cancer (NSCLC) #Oncology #Orphan drugs #Pfizer

Orphan designated precision drug approved in US for NSCLC

The US Food and Drug Administration (FDA) has approved orphan drug encorafenib (Braftovi) with binimetinib (Mektovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA also approved the FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion diagnostics for encorafenib with… Read More

#News #Regulatory

The European Medicines Agency building
#EFPIA #Europe #Orphan drugs #Pharmaceuticals #Rare disease #Regulatory

Proposed changes to EU regulation risks progress on orphan drugs

Plans to overhaul the EU regulation on rare disease therapies risk undermining two decades of progress, a new report claims. The assessment, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA), was conducted by Dolon, a strategic consultancy specialising in rare diseases. The European Orphan Medicinal Product Regulation… Read More

#News #Regulatory

Kidneys
#Calliditas Therapeutics #FDA #Orphan drugs #Phase II trial

FDA orphan drug designation for Alport syndrome with setanaxib

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Calliditas Therapeutics for the treatment of Alport syndrome with setanaxib. Based on supportive pre-clinical work, Calliditas plans to initiate a randomised, placebo-controlled Phase II clinical study in Alport syndrome with around 20… Read More

#News

FDA
#Cancer research #FDA #Immunotherapy #Oncology #Orphan drugs

Orphan status granted to lymphoma maintenance therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 4SC’s resminostat (Kinselby) for cutaneous T-cell lymphoma (CTCL). Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor that potentially offers an approach to treating different kinds of cancer. The company demonstrated that resminostat is… Read More

#News #Regulatory

siRNA
#DTx Pharma #FDA #Orphan drugs #Rare disease #siRNA

siRNA therapy for rare disease granted orphan status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to DTx Pharma’s DTx-1252, an investigational small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). CMT1A is a progressive, neuromuscular, autosomal-dominant disease that leads to life-long loss of muscle… Read More

#News

siRNA
#FDA #Orphan drugs #Paediatrics #Rare disease #siRNA #SiSaf

Therapy for rare skeletal disorder granted orphan status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to SiSaf’s small interfering RNA (siRNA) therapeutic for skeletal disorder Autosomal Dominant Osteopetrosis Type 2 (ADO2). In addition, due to the serious manifestations of this rare disease in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for… Read More

#News #Regulatory

Scientist in laboratory
#Orphan drugs #Rare disease #Rare Disease Day #Terebellum

Rare disease market access guide launched

A new strategic guide, intended to help manufacturers bring rare disease products to market, has been launched to mark Rare Disease Day (February 28). In the guide, Terebellum (a subsidiary of AscellaHealth) shares tips on how industry stakeholders can create an effective market access strategy, giving their treatment the best chance… Read More

#Business & Investment #News

Tau proteins
#Asceneuron #Ferrer #License agreement #Neurodegenerative disorders #Neurology #Orphan drugs #Tau protein

Ferrer secures worldwide rights to PSP drug

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.  The terms of the agreement include an upfront fee and multiple development, regulatory and commercial milestone… Read More

#Business & Investment #News

Stamp of approval
#European Commission #Orphan drugs #Paediatrics #Phase III trial #Regulatory #UCB

Fenfluramine approved in the EU for LGS seizures

UCB’s Fintepla (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).  It has received authorisation as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.  The approval was based on safety and… Read More

#News #Regulatory

#Endogena Therapeutics #FDA #Ophthalmology #Orphan drugs #Priority Review #Retinitis pigmentosa

FDA Fast Track Designation for retinitis pigmentosa treatment

The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development programme.   Fast Track is a process designed to enable patients to benefit earlier from important new drugs for serious conditions. … Read More

#News